Sabby Management’s Ionis Pharmaceuticals IONS Stock Holding History

Sabby Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-84,600	Closed	-$2.84M	–	196
2021 Q3	$2.84M	Buy	84,600 +6,600	+8%	+$249K	0.38%	38
2021 Q2	$3.11M	Buy	78,000 +23,312	+43%	+$913K	0.44%	28
2021 Q1	$2.46M	Buy	+54,688	New	+$3.05M	0.48%	41
2017 Q2	–	Sell	-115,694	Closed	-$5.39M	–	236
2017 Q1	$4.65M	Buy	+115,694	New	+$5.2M	0.25%	51
2016 Q2	–	Sell	-7,002	Closed	-$226K	–	312
2016 Q1	$284K	Buy	+7,002	New	+$284K	0.01%	242
2014 Q1	–	Sell	-13,157	Closed	-$638K	–	259
2013 Q4	$524K	Buy	13,157 +1,494	+13%	+$53.2K	0.03%	149
2013 Q3	$438K	Buy	+11,663	New	+$348K	0.03%	161

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Sabby Management's IONS Position: Q4 2021 in Review

Sabby Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2021, closing a stake of 84,600 shares — an estimated $2.84M sold.

Sabby Management first reported a position in IONS in Q3 2013 and held it in 7 quarters. The position peaked at $4.65M in Q1 2017. 341 funds tracked by Wall St. Rank hold IONS as of Q4 2021.

Sabby Management reported no remaining Ionis Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Sabby Management sold 84,600 Ionis Pharmaceuticals shares in Q4 2021, an estimated $2.84M.
Sabby Management first reported a position in Ionis Pharmaceuticals in Q3 2013 and held it in 7 quarters.
Sabby Management's Ionis Pharmaceuticals position peaked at $4.65M in Q1 2017.
341 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2021.

Based on Sabby Management's 13F filing for Q4 2021, filed 14 Feb 2022.